ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3161

The Association Between HLA Genetic Susceptibility Markers and Sonographic Enthesitis in Psoriatic Arthritis

Ari Polachek1, Richard J. Cook2, Vinod Chandran1, Fatima Abji1, Dafna D Gladman3 and Lihi Eder4, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, 3University of Toronto, Toronto, ON, Canada, 4Rheumatology, University of Toronto, Women's College Hospital, Toronto, ON, Canada

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Enthesitis, genetics, Psoriatic arthritis and ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, November 16, 2016

Title: Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology II

Session Type: ACR Concurrent Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose: Enthesitis is an important pathophysiologic component in psoriatic arthritis (PsA). Ultrasound is emerging as an optimal method to evaluate enthesitis. HLA genes are implicated in the pathogenesis of PsA. Little is known about the relation between HLA genetic susceptibility markers and enthesitis in PsA patients. Hence, our aim was to examine the association between HLA genetic susceptibility markers and sonographic enthesitis in patient with PsA.      

Methods: A cross-sectional analysis was performed in patients followed at a large PsA cohort. Sonographic enthesitis was assessed according to the MAdrid Sonography Enthesitis Index (MASEI) scoring system which quantifies the extent of sonographic entheseal abnormalities in 12 entheseal sites adjacent to large joints. Total MASEI was further categorized into: bone scores (enthesophytes, erosions) and soft tissue scores (structural entheseal changes, vascularization, bursitis). HLA genotyping was performed using sequence-specific oligonucleotide probes. The association between 6 HLA susceptibility markers of PsA and the severity of sonographic enthesitis (by MASEI) was assessed using multivariate linear regression models adjusted for age, sex, BMI and disease duration.

Results: Two hundred and twenty five patients were included, 57% male with mean (s.d.) age of 55.8 (12.9) years and PsA duration of 16.4 (12.3) years. The majority of the patients were Caucasians (88%). The frequencies of the HLA alleles were: HLA-B*27: 15.1%; HLA-B*38: 18.2%; HLA-B*39: 4.9%; HLA-B*44: 21.8%; HLA-B*08: 17.3% and HLA-C*06: 27.5%. In the univariate analysis HLA-B*27 (β 3.8, p=0.005) was associated with more severe enthesitis while HLA-C*06 (β -2.4, p=0.03) was associated with less severe enthesitis. The results of the multivariate regression model are shown in Table 1. The interaction between HLA-B*27 and PsA duration was statistically significant, showing an increasing effect of HLA-B*27 with longer PsA duration (p=0.004). The results remained essentially the same after restricting the analysis to Caucasians. Other predictors of enthesitis severity included male gender (p=0.02) and BMI (p<0.001). The interaction between HLA-B*27 and PsA duration was also associated with higher MASEI-bone scores (p=0.002). HLA-B*27 was also associated with higher MASEI-soft tissue scores (p=0.01).

Conclusion: HLA-B*27 is associated with the severity of sonographic enthesitis in PsA, particularly in patients with longer disease duration. This finding highlights the potential role of genetic variants to predispose to severe enthesitis in patients with PsA.      

Table 1: Multivariate Regression Model assessing the association between HLA alleles and MASEI score (Total MASEI include active GS and PD abnormalities)

Variable*

Multivariate Model

(N=225)

 

Multivariate Model (Caucasians)

(N=196)

 

Estimate (95% CI)

P value

Estimate (95% CI)

P value

HLA-B*27

4.64 (0.39, 8.89)

0.03

4.45 (0.12, 8.87)

0.04

HLA-B*27* PsA Duration

4.78 (1.54, 8.02)

0.004

4.62 (1.38, 7.87)

0.005

HLA-C*06

-2.27 (-5.62, 1.06)

0.18

-1.52 (5.08, 2.03)

0.40

Age (10 years)

1.02 (-0.26, 2.31)

0.12

1.37 (0.01, 0.27)

0.047

Sex

3.71 (0.67, 6.67)

0.02

4.32 (1.10, 7.54)

0.008

BMI

0.56 (0.31, 0.81)

<0.0001

0.56 (0.30, 0.82)

<0.0001

PsA Duration (10 years)

0.54 (-0.90, 2.00)

0.46

0.54 (-0.95, 2.04)

0.47

*This model included variables that were statitically significant in the univariate analysis GS – Gray scale, PD – Power Doppler

 


Disclosure: A. Polachek, None; R. J. Cook, None; V. Chandran, None; F. Abji, None; D. D. Gladman, AbbVie, Amgen, BMS, Celgene Corporation, Janssen, Novartis, Pfizer, UCB, 2,AbbVie, Amgen, BMS, Celgene Corporation, Janssen, Novartis, Pfizer, UCB, 5; L. Eder, None.

To cite this abstract in AMA style:

Polachek A, Cook RJ, Chandran V, Abji F, Gladman DD, Eder L. The Association Between HLA Genetic Susceptibility Markers and Sonographic Enthesitis in Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-association-between-hla-genetic-susceptibility-markers-and-sonographic-enthesitis-in-psoriatic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-association-between-hla-genetic-susceptibility-markers-and-sonographic-enthesitis-in-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology